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1. Introduction 
Ulcerative colitis (UC) is a chronic gastrointestinal inflammatory disorder and is one of the 
inflammatory bowel diseases (IBD) along with Crohn disease (CD). CD can involve any area 
of the gastrointestinal (GI) tract and has features of transmural disease, skip lesions and 
mucosal granulomata. UC, on the other hand, principally involves the colon for a variable 
length, and comprises confluent superficial inflammation. In addition, some individuals 
may be termed to have IBD unclassified (IBDU): a situation where there are clear diagnostic 
features of IBD, but no definitive features of either UC or CD. Over time many individuals 
with IBDU are reclassified as UC or CD. At present CD and UC are considered to be 
incurable, although colectomy can be seen as a surgical cure for UC. Furthermore, the 
pathogenesis of these conditions remains unclear, although understanding is increasing 
rapidly.  
The onset of UC can be in any age, from the first year of life. The peak age of onset, 
however, is between 15 and 35 years of age. Overall rates of UC climbed through the last 
decades of the 20th century. Recent paediatric data suggests that rates of UC have been static 
in a number of countries. In some, however, UC incidence has continued to increase. In 
countries where IBD was previously uncommon, UC incidence rates are also noted to be 
increasingly recently. When diagnosed in children of any age, these individuals face a long-
term condition with remitting-relapsing features. Children may have significant 
interruption to daily activities and consequent impact upon quality of life (QOL). A number 
will have complications of disease and some will require colectomy during childhood. 
Because of the multiple aspects of UC and the various adverse impacts, children and 
adolescents with UC should be considered separately to adults with UC and require a 
multidisciplinary approach to management to ensure that all aspects are considered in 
optimal fashion. 
2. Pathogenesis of IBD 
2.1 Current hypothesis of causation of UC 
At the present the precise cause of IBD is unknown. The best accepted hypothesis is that UC 
develops in individuals at genetic risk as a result of interactions between the intestinal 
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microflora and the host innate immune responses, leading to dysregulated immune 
responses and to consequent inflammation.  Environmental factors are also important.  
2.2 Genetic influences in the development of UC  
The familial nature of UC and of CD has been recognised for many years. Over the last 
decade or so, international collaborative groups have focused on identifying the genetic 
elements contributing to the risk of IBD, with many key discoveries. Over 100 loci are now 
reported in association with IBD. There is some overlap with many loci important for both 
CD and UC. However, more than 20 loci are specific for UC. These include genes encoding 
for cytokines (e.g. interleukin (IL)-10, IL-22 and IL-26) and others whose function are unclear 
(e.g. ARPC2) (Thompson and Lees 2011; Cho and Brant 2011). 
Recent studies have used genome wide association studies (GWAS) to examine particular 
genetic elements important in early-onset (paediatric) UC and have demonstrated the 
involvement of several particular genes (Anderson et al 2011; Henderson et al  2011a). 
Important mutations have been shown in IL-27 (implicated in Th17 cell function), CAPN10 
(involved in endoplasmic reticulum stress responses), MTMR3 (component of autophagy 
reactions), and several other genes.     
2.3 The intestinal flora and UC 
The intestinal flora is clearly critical in the development of IBD. In specific animal models of 
gut inflammation, exclusion of the bacterial flora prevents or delays the onset of the 
inflammatory changes. In the human setting, excluding the flow of faecal effluent from an 
involved segment of bowel (i.e. defunctioning a segment of the bowel) leads to 
improvement of inflammation.  Furthermore, antibiotic treatment of individuals with active 
CD can lead to improvement, whilst probiotic therapies that modify the intestinal flora have 
similar effects in the setting of UC.  
At present, however, there is no evidence for one specific organism or group of organisms 
being the causative agent(s) of IBD. Candidate organisms include Mycobacterium 
paratuberculosis (MAP), Escherichia coli, and mucous-associated flora. Recent work has 
focused on several mucous-associated flora and indicates high rates of specific organisms in 
children with active IBD compared to controls. Campylobacter concisus is one example of a 
bacterium that may play roles in the development of IBD. Our work in Australian children 
has illustrated that this organism is frequently present at the time of diagnosis of CD in 
children (Man et al 2010). Ongoing studies from the UK also indicate that this organism is 
more often present in newly diagnosed UC than in controls (Mukhopadhya et al 2011). 
However, at present there is not sufficient data to indicate that this pathogen is the specific 
causative agent in IBD. 
2.4 Other environmental factors 
Other environmental factors are also relevant to the development of UC. Appendectomy for 
appendicitis is associated with lower rates of UC, whilst smoking also can be protective 
(Bastida et al 2011). Exposure to second-hand smoke (passive smoking) in children does not 
appear to provide any protection against the development of UC (Mahid et al 2007). 
However, one series suggested that patients with UC exposed to passive smoke had 
increased extra-intestinal manifestations (van der Heide 2011), but this has not been 
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described by others. Other factors that are shown to be protective against UC include having 
a vegetable garden as a child and breast-feeding (Gearry et al 2010). 
2.5 Dysregulated immune responses 
Disrupted innate defence mechanisms in the gut are also critical to the development of the 
chronic inflammation as seen in IBD.  Many of the genes implicated in IBD encode for 
proteins involved in innate protection of the mucosa. Altered barrier function, leading to 
increased epithelial permeability, is clearly described. It is unclear if this is a primary event, 
or if it occurs secondary to gut inflammation.  Variation in innate antibacterial proteins, such 
as defensins, may contribute to altered host responses (Ramasundara et al 2009). Altered 
immune responses are likely also important. T helper cell type 1 (Th1) responses have 
traditionally been implicated in CD, whilst Th2 or a combination of both pathways seen as 
relevant to UC. More recent understanding suggests that T regulatory cells (Tregs) have key 
roles in UC. 
3. Epidemiology of UC in children and adolescents 
UC can occur in children of any age, but rates tend to increase with age. Most large cohorts 
illustrate that UC comprises around 25-30% of paediatric IBD (the majority of children with 
IBD are diagnosed with CD). Family history of IBD (CD or UC) is commonly seen in 
children diagnosed with UC. 
Two large cohorts have examined the epidemiology of paediatric UC in different areas of 
the USA. The earlier study retrospectively reviewed 171 children diagnosed with UC in two 
academic centres in North-East USA (Hyams et al 1996). The children in the cohort ranged 
from the second year of life to almost 18 years of age (mean 11.7 yrs). Just over one third of 
the group were aged less than 10 years at diagnosis. The gender distribution slightly 
favoured males (55%) and the population was predominantly Caucasian (95%). A first 
degree family history was present in 11%. Most had symptoms for less than 3 months, but 
18% had symptoms for more than 6 months duration before diagnosis. At diagnosis, mild 
disease was present in 43%, with moderate or severe disease in 57%. The majority of the 
mild group had proctitis or proctosigmoiditis, whilst almost the entire moderate/severe 
group had left-sided or pan-colonic disease. Ninety percent of the mild group and 80% of 
the mod/severe group had cessation of symptoms within the first six months of therapy. 
Almost two thirds of the mild group had inactive disease in the second six-month period 
after diagnosis, with only one child having continuous disease in this time period. Over the 
same period, 11% of the moderate/severe group had continuous disease, with a further 44% 
having intermittent/chronic disease course. Disease distribution did not appear to influence 
this course. Twenty-seven percent of the mild group received corticosteroids by 12 months 
after diagnosis, contrasting with 70% of the moderate/severe group needing this therapy 
over the same time. Overall, the one year colectomy rate in this group of children was 9% at 
12 months and 19% at 5 years. Age less than 10 years did not influence colectomy rates, but 
initial disease severity was associated with increased risk for colectomy overall.  
More recently was a study of prospectively recruited children with diagnosis of IBD from 
across the state of Wisconsin for the first two years of the 21st century (Kugathasan et al 
2003). Sixty children with UC were identified within a total of 199 children with IBD (30% of 
the total). The UC cohort had an average age of 11.8 yrs and 55% were male. There was no 
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association between UC and rural or urban location and 87% were Caucasian. Eleven 
percent had a first or second-degree family member with IBD. Ninety-eight percent of this 
group had diarrhoea at diagnosis, with bleeding in 83%, pain in 43% and weight loss in 
38%.  
The mean period of symptoms prior to diagnosis was 3 months in this group. Most of the 
group (90%) had pan-colonic disease, with the rest having left-sided location. ESR was 
normal in 35% and albumin was normal in 68% of the cohort. 
Follow-up data including response to therapy, or other outcomes were not reported in this 
cohort.  
A recent report examined the incidence of UC across Scotland in two distinct time periods 
(1990-95 and 2003-8) (Henderson et al 2011b). Compared to the earlier time period, the 
incidence was greater in the more recent cohort (1.59/100,000/yr versus 2.06/100,000/yr; 
p=0.023). This equates to a 30% increase in paediatric UC over this period. There was a male 
predominance overall and age-adjusted incidence figures showed increases in males but not 
females over time.  Another recent study utilised Canadian health data and demonstrated a 
modest rise on the prevalence of UC from 16.2 to 19.7/100,000 over the period of 1994 to 
2005 (Benchimol et al 2009).  
The overall trends in the rates of UC were reviewed recently (Benchimol et al 2011). This 
article assessed 139 studies reporting rates of paediatric-onset IBD across 32 countries, both 
developing and developed. Overall, rates of IBD were clearly shown to be increasing with 
varied rates between countries. Not all the studies applied statistical analysis to changing 
rates over time: overall one-fifth of the studies showed increasing UC in children. 
A recent report has characterised patterns of UC in Japanese children with direct 
comparison to adults in that country (Ishige et al 2010). A long-standing register was 
examined for the patterns of disease in children and adults. In total, 37,846 individuals with 
UC were included: 5.9% were aged less than 16 years of age. The children more commonly 
had positive first-degree family history, more severe disease at diagnosis and had more 
extensive colitis than adults. Family history of IBD was seen in 4.3% of the children (less 
than in comparable European cohorts). 
Reports from the middle part of the 20th century illustrate a predominance of UC in cohorts 
of IBD. As noted above, most recent cohorts reported in the western world demonstrate 
much higher rates of CD than UC.  One study has however, demonstrated that this is not a 
universal change (Lehtinen et al 2011). This study of rates of paediatric IBD in Finland over 
16 years showed increasing rates of IBD over this time (rates increased by 6.5% per annum. 
In addition, rates of UC increased from 4/100,000 to 9/100,000 over the period from 1992 to 
2003. These regional differences illustrate the importance of environmental factors in the 
development of UC. 
 Interestingly, recent reports from Asia, where IBD was previously considered to be rare, 
have shown increasing rates of UC (more so than with CD) (Goh and Xiao 2009). This 
pattern of differing rates across the globe also illustrates the importance of environmental 
factors.  
4. Phenotypic features of UC 
UC has traditionally been seen as a chronic inflammatory condition of the colon, with 
inflammation extending for variable distances from the anus. Disease patterns include 
proctitis (distal changes only), left-sided colitis or pan-colitis. 
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Inflammation is superficial, with acute and chronic changes. This pattern contrasts with CD, 
where disease can involve any section of the gastrointestinal tract (from mouth to anus), 
with trans-mural inflammatory changes and the presence of the specific findings of 
granulomas. Perianal disease is a feature of CD and not UC. 
The adult-based Montreal disease classification system for IBD included three types of UC: 
proctitis (E1), left-sided disease (E2) or disease proximal to the splenic flexure (E3) 
(Silverberg et al 2005). The recent Paris classification has adjusted the Montreal system for 
paediatric UC by the addition of E4 (disease proximal to hepatic flexure), and S1 (ever 
severe UC) (Levine et al 2011). 
Recent studies demonstrate that non-specific gastritis may be seen in combination with 
colonic disease in UC (Hori et al 2008). Homing of lymphocytes from the colon to the 
stomach may explain some of these events (Berrebi et al 2003). In addition some authors 
describe so-called “back-wash” ileitis, with minor changes present in the distal ileum, as an 
occasional feature of UC. 
UC is associated with various extra-intestinal manifestations (EIM) of disease, such as skin, 
eye and liver disease. EIM were noted in 285 of a cohort of 1009 newly diagnosed patients 
with IBD – most of these occurred within the first 12 months after diagnosis (Dotson et al 
2011).  In a cohort of 211 children with UC from the UK, 1 had skin manifestations and 5 had 
liver disease at diagnosis (Sawczenko et al 2003). 
Several studies of large paediatric cohorts have illustrated key phenotypic features of UC. 
These studies demonstrate that many children have pan-colitis at diagnosis, with few 
having proctitis and a small number having left-sided disease. Furthermore, many children 
with limited disease at initial assessment have extension to pan-colonic disease over the first 
2-3 years of their disease. This pattern in children contrasts greatly with adult UC, where 
proctitis is prominent and pan-colitis seen less commonly. 
A study based in Scotland evaluated the features of 99 children with UC at diagnosis and 
over the subsequent years, and compared these features of a cohort of adult-onset UC 
(Van Limbergen et al 2008). UC was extensive (pan-colonic) in 82% of the children at the 
time of diagnosis. In contrast, this pattern was seen in just 48% of adults (p <0.0001). 
Almost half (46%) of the children without extensive disease initially progressed to 
develop extensive colitis during follow-up. One third of the group required 
immunomodulatory therapy within 12 months of diagnosis. In addition, the median time 
to first surgery was substantially shorter in the patients with childhood-onset than in 
adult-onset patients.  
A similar cohort was described from France, in which 112 children were characterised at 
diagnosis and their progress followed for at least 2 years (Gower-Rosseau et al 2009). At 
diagnosis, 28% of the children had proctitis, 35% left-sided colitis, and 37% extensive colitis. 
The disease course of this group also was characterized by disease extension in 49% of 
patients. Delay in diagnosis for more than 6 months and a positive family history of IBD 
were associated with an increased risk of extension of disease. Eight percent of this group 
had colectomy within 12 months of diagnosis. By 3 years, 15% had colectomy and by 5 years 
20% had undergone colectomy. The risk of colectomy was increased if EIM were present at 
diagnosis (hazard ratio = 3.5 (1.2-10.5)). In addition, with regards the group with less 
extensive disease initially, those who had disease progression had much greater risk of 
needing colectomy than those who continued to have restricted disease. These two well-
described cohorts of children from Europe have illustrated a number of key aspects of the 
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natural history and outcomes of paediatric UC, and have emphasised that paediatric-onset 
disease has many key differences from the same disease beginning in adulthood.   
5. Presentation patterns of UC 
Bloody diarrhoea is the most common presenting feature in paediatric UC. However, 
children may also have less specific symptoms of abdominal pain, anaemia, or lethargy. 
In a large cohort of British children (n=172) newly diagnosed with UC, diarrhoea was seen 
in 72%, bleeding in 84%, pain in 62%, weight loss in 31%, and lethargy in 12% (Sawczenko et 
al  2003). Arthropathy, nausea and secondary amenorrhoea were seen less commonly.  
Idiopathic acute pancreatitis (AP) is a further atypical pattern of presentation with UC. 
Broide et al (Broide et al 2011) retrospectively evaluated a cohort of 12 individuals with IBD 
who had presented initially with AP: 10 of these were children. Eight of these 10 children 
had colonic disease (four with UC). Although the median time between the episode of AP 
and the onset of IBD was 24 weeks, the longest duration was 156 weeks. 
Acute severe UC (or fulminant colitis) can be seen at diagnosis or at subsequent 
exacerbations in adults or children with UC.  In adults this pattern is defined as more than 
six bloody motions daily along with tachycardia, fever, anaemia or elevated ESR (one of 
these required for the definition). In children acute severe colitis can be defined as Pediatric 
Ulcerative colitis activity index (PUCAI) of 65 points or greater.  
Historically, acute severe colitis was seen as a medical emergency with a high case fatality 
rate. It remains a life-threatening condition, with risk of various complications. Hence early 
recognition and optimal management of this condition is critical. 
6. Growth and nutrition in paediatric UC 
Children with UC commonly have weight loss at presentation. Case series suggest that up 
to 65% of children with UC have a history of weight loss at diagnosis (Griffiths et al 2004). In 
addition to weight loss and/or failure to continue gaining weight normally, children 
diagnosed with UC may also have a history of interrupted or impaired linear growth. As 
many children with UC are diagnosed in adolescence, before or during their pubertal 
growth spurt, perturbation of normal linear growth at the time of the expected pubertal 
growth spurt can be a significant complication of paediatric IBD. For these reasons, ongoing 
attention to growth and nutrition from the time of diagnosis and thereafter, is a crucial 
aspect of management of UC in children and adolescents. These concerns, however, are 
even more pertinent in children with CD, which has much greater impact on growth and 
nutrition than in paediatric UC. 
6.1 Overweight and obesity in IBD 
Although most concern about the nutritional impact of IBD in children is with regards 
under nutrition, recent data indicates that more children are overweight (BMI > 85%) 
and/or obese (BMI > 95%) at the time of diagnosis of IBD. These changes may simply reflect 
recent overall changes in weight in children and adolescents across many countries (i.e. 
increasing overweight/obesity). However, overweight/obese status has important 
implications for children with IBD. 
In a group of 166 children with newly diagnosed IBD in Wisconsin, USA, 17.6% of the 
children with UC were overweight/obese (Sondike et al 2004).  More recently, 23.3% of a 
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separate group of 1598 American children with known CD and UC were noted to be 
overweight/obese (Long et al 2011). The rate of over nutrition was markedly greater (30%) 
in the children with UC in this group than the children with CD. In this cohort recruited 
from a number of paediatric centres, overweight/obesity status was associated with 
African-American ethnicity and Medicaid insurance. In addition, prior surgical intervention 
was linked with overweight/obese status in the children with CD, suggesting that the 
presence of over nutrition may be associated with a more severe disease course. 
Overweight/obese status may also make medical therapies more difficult, and increase 
surgical morbidities. In addition, it may increase psychological outcomes in the setting of 
children with a chronic disease, making them stand out even more from their peers.   
7. Investigation and diagnosis of UC in children and adolescents 
7.1 Consideration of diagnosis of IBD 
The diagnosis of UC relies firstly upon consideration of the diagnosis. Children with 
atypical symptoms may be reassured and symptoms not assessed further if practitioners are 
not aware that UC can present at any age. As noted above, presentation patterns in children 
with UC vary, with most typical symptoms being bleeding, diarrhoea and pain. Family 
history of IBD (especially in first degree family members) should further raise suspicion of 
possible IBD.   
A presentation with bloody diarrhoea in a child requires a series of assessments. In infants, 
the differential of this presentation includes eosinophilic (allergic) colitis, infection, surgical 
conditions (such as intussusception) and complications of congenital conditions (such as 
Meckels diverticulum). In older children, infection is an important differential. Functional 
constipation with bleeding from distal causes (anal fissures) and perianal Streptococcal 
infection may be important to exclude. 
7.2 Approach to possible IBD/UC 
A detailed history should clarify the features of the gastrointestinal symptoms, especially 
patterns of pain and bowel habit. Appetite, energy levels (lethargy), and weight changes 
should be documented clearly. The presence of any extra-intestinal features should be 
detailed, including skin, eyes, joint and systemic symptoms. Past history of gastrointestinal 
symptoms and diseases should be noted, along with family history of IBD or other GI 
conditions. The extent to which the child has been able to continue daily activities should be 
carefully documented also: this includes attendance at school, school performance, social 
interactions, ability to undertake sports or other hobbies, and general interest in these 
activities. Clarification of current immunisations status is important and a catch-up plan 
arranged if required. Confirmation of past history of varicella or of antibody protection 
against this infection will be relevant if this vaccine is not included in the routine schedule.  
Physical examination should include a search for extra-intestinal manifestations of IBD (skin 
for erythema nodosum or pyoderma gangrenosum, joints for arthalgia/arthritis and mouth 
for ulceration or lip swelling), documentation of oedema, anaemia and clubbing, and 
comprehensive examination of abdomen and perianal region. The abdomen should be 
examined for signs of organomegaly, tenderness and mass. Perianal region should be 
examined for signs of skin tags, fissures, fistulas or collections. Examination of lower spine 
and ileo-sacral region may be relevant if back pain is a feature. 
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In addition, to these undertakings a close examination of growth and nutrition is also 
relevant. This should begin with detailed examination for nutritional deficiencies, such as 
anaemia, oedema and skin changes. Current weight and height measurements should be 
recorded and plotted on a standard age-appropriate growth chart. BMI should be 
calculated. Retrieval of past weight and height measurements is often helpful to fully 
document the child’s growth history and patterns over time. These measurements can be 
used to calculate recent height velocity. Parental and family growth patterns are also 
important to define. In peri-pubertal children Tanner stage should be documented  
to clearly define current pubertal status. Establishment of the child’s current bone age 
(using radiograph of the child’s left wrist) will be helpful in interpreting any linear 
growth delay. 
7.3 Initial investigations  
The first investigations in the setting of possible UC include the collection of multiple stool 
samples for microscopy and culture to exclude enteric infection. Testing should include the 
request for specific organisms including Clostridium difficile.  Further tests should include 
blood tests for serum markers of inflammation (as per below section), and stool 
inflammatory markers (see below section) if available.  
Other tests may be indicated in the initial work-up depending on the clinical context – two 
further examples are investigations for possible Coeliac disease (tissue transglutaminase and 
total immunoglobulin A) and tests for pancreatitis (amylase and lipase). 
If infection is excluded and the results of initial tests indicate inflammatory events, then 
endoscopic assessment should next be undertaken. International guidelines recommend 
colonoscopy (with terminal ileal intubation) and upper gastrointestinal endoscopy for the 
assessment of possible IBD in children. Multiple biopsies from all segments of the upper and 
lower gut are required to ensure full assessment of the GI tract. 
Assessment of the small bowel is also required to exclude the presence of small bowel CD 
and to distinguish from UC. The preferred test in many centres is now small bowel 
magnetic resonance imaging (MRI), known either as MRI enterography or small bowel 
series MRI. This modality has better sensitivity and specificity than some other modalities 
that been used in the past, such as barium meal and follow-through or technetium-
labelled white cell scan. Capsule endoscopy and positron-emission tomography (PET 
scanning) also have high test utility, but remain less available or more expensive options 
at present. 
7.4 Further baseline assessment after confirmation of UC 
Other baseline testing should include assessment of renal function (serum urea and 
creatinine), liver chemistry (Bilirubin, ALT, AST, GGT, ALP and albumin), electrolytes and 
minerals (sodium, potassium, chloride, calcium, phosphate, magnesium and zinc), and 
nutritional or absorptive markers (iron, ferritin, vitamin B12, folate and Vitamin D).  
Serological markers may be helpful in differentiating between CD and UC if these are 
available. The presence of anti-neutrophil cytoplasmic antibodies (p-ANCA) is more 
common in UC, whereas anti-Saccharomyces cerevisiae antibodies (ASCA) are more 
frequently found in CD. 
It also may be appropriate to define TPMT activity at the time of baseline assessment, so that 
this result is available in the event of future prescription of thiopurines. 
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7.5 Endoscopic and histologic features of UC 
The typical endoscopic appearance in UC is of confluent disease extending proximally from 
the rectum for a variable distance. Ulcers, erythema, loss of normal vascular pattern, 
granularity, increased friability and the presence of pseudopolyps are common findings 
(Figure 1). An absence of skip lesions is one aspect to assist in excluding CD. Although 
rectal sparing is typically seen as a feature of CD, some authors have suggested that this 
may be present in UC (Rajwal et al 2004).  
Histologically, typical changes of UC include a continuous pattern of acute and chronic 
mucosal inflammation, with crypt distortion, crypt abscesses, and goblet cell depletion. The 
absence of granulomas or of patchy changes helps to exclude from CD. 
 
 
Fig. 1. Typical endoscopic appearance of severe colitis, with loss of normal mucosal vascular 
patterns, oedema, friability and ulceration 
7.6 Radiologic findings in UC 
As mentioned above, examination of the small bowel should be included as an essential part 
of the work-up for likely IBD. The principal rationale is to define the extent or presence of 
small bowel CD, which may not be evident on standard endoscopic assessment. In UC, the 
small bowel radiology assessment would be expected to be normal.   
Plain abdominal radiographs may show changes of colitis in UC, with thumb-printing, 
wall thickening or featureless mucosal surface. Plain radiographs should also be 
considered in the assessment of fulminant (acute severe) colitis where abdominal 
tenderness or distension is present to ascertain if toxic megacolon is present. Abdominal 
ultrasound may also be used to define colonic wall thickening and due to improved 
sensitivity is being considered more.    
In the event of incomplete colonoscopy (such as in the settings of colonic stricture or very 
severe mucosal disease), imaging may be helpful to confirm the proximal extent of the 
colonic involvement. Magnetic resonance imaging or labelled white cell scans may be 
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helpful. Barium enema examinations can be considered if other tests are not feasible or are 
unhelpful, but are no longer first-line investigations in children. 
7.7 Differentiation between CD and UC 
A full assessment is important to definitively establish a diagnosis of IBD and also to assist 
in distinguishing between UC and CD. Almost two thirds of children with CD have upper 
gut and/or small bowel changes at diagnosis. These may be the only locations of disease, or 
may help to delineate the diagnosis in the setting of pan-colitis where there are no other 
defining features of UC or CD present.    
The European Society for Paediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) established the Porto criteria in 2005 (ESPGHAN 2005). This consensus 
statement provided a set of recommendations for the key elements for the diagnosis of IBD 
and also considered the important features to distinguish between CD and UC. A Spanish 
group has subsequently reviewed a cohort of 108 patients according to the application of the 
Porto criteria (Martin De Carpi et al 2011).  Overall they noted that these criteria had been 
followed in 49% of the children (with a higher percentage after the publication of the criteria 
than prior to this). Ileocolonoscopy was undertaken in 85.2% of children with multiple 
biopsies obtained. Upper endoscopy was undertaken in 39% of children prior to and 72% of 
the group after the publication of the Porto criteria. These authors noted that the 
introduction of the criteria lead to a change in clinical practice. 
A report from a NASPGHAN working group considered the key elements in differentiating 
between UC and CD in children or adolescents (NASPGHAN 2007). This report aimed to 
address controversies in the assessment of IBD in children and to develop an algorithm to 
enhance practitioner agreement and consistency in the diagnosis and classification of CD 
and UC. Clarification of the features of IBD-Unclassified (IBDU) was also undertaken.  
8. Inflammatory markers and disease activity in paediatric UC 
8.1 Assessment of disease activity: Pediatric UC Activity Index 
Recently the Pediatric UC activity index (PUCAI) has been developed as a standardised 
measure of activity in children with UC (Turner et al 2007). A well-defined process was used 
to identify six critical elements (from an initial group of 41 variables). These six variables are 
abdominal pain, rectal bleeding, stool consistency, nocturnal stools, number of stools each 
24 hours and interruption to normal activities. The PUCAI correlates closely with other 
indicators, such as physician global assessment and endoscopic scores (Turner et al 2009). 
This validated score, which is simple and non-invasive, can now be used to assess disease 
activity and to monitor changes in activity following intervention. It can also be used to 
guide management decisions, such as in the context of acute severe UC. 
8.2 Relapse and remission in paediatric UC 
UC tends to follow a relapsing and remitting course, with periods of disease control 
interrupted by relapses or flares of symptoms. Active disease in children with UC can be 
defined in terms of symptoms, serum or faecal markers of inflammation and increased 
mucosal inflammatory changes.  In contrast, remission in children can be defined clinically 
or symptomatically (resolution of symptoms), biochemically (normalisation of abnormal 
inflammatory markers) and histologically (mucosal healing). Mucosal healing is 
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increasingly recognised as an important goal in the initial management of IBD, especially in 
children with many years of disease ahead of them. Attaining mucosal healing may in turn 
lead to modification of the long-term disease course in UC (Colombel et al, 2011). Although 
mucosal healing is now seen as an ideal state, in terms of long-term outcomes, this degree of 
monitoring requires repeated endoscopic and colonoscopic assessment, which is often not 
feasible or possible in children.  
8.3 Standard serum inflammatory markers 
Standard serum markers of inflammation include ESR, CRP, platelets and albumin. These 
markers are easy to measure in most routine clinical laboratories, but tend to have low 
specificity and sensitivity for gut inflammation in children with UC. Mack et al measured 
ESR, platelet count, albumin level along with haemoglobin in 134 children with newly 
diagnosed UC (Mack et al 2007). All four of these markers were normal in 54% of the 
children with mild UC, whilst 4.3% of those with moderate-severe UC had normal tests. ESR 
was the most useful test in this cohort. In addition, disease extent was linked with the 
number of abnormal tests.   
In a small cohort of 30 children with diagnosed with UC at Sydney Children’s Hospital 
(Sydney, Australia), 54% had elevated ESR, whilst platelets were elevated in 13%, CRP high 
in 29% and albumin abnormal in 33% (Day et al, unpublished data). There was no 
correlation between disease location and the number of abnormal results in this group. 
In a further, recently reported, cohort of 102 Canadian children with newly diagnosed UC, 
CRP levels were found to be elevated in 41% of those with mild disease and 60% of those 
with moderate-severe disease (Tsampalieros et al 2011).   
8.4 Faecal markers of inflammation 
Stool samples can be used to measure various markers of gut inflammation. The presence of 
faecal white cells can indicate the presence of gut inflammation but are also present in 
various enteric infections. Faecal white blood cells may be degraded if the sample is not 
viewed promptly. Elevated levels of faecal α-1-antitrypsin, a protein that is stable in stool, 
can reflect mucosal inflammation as a breach of the epithelium may lead to a protein losing 
state. Neither of these indicators has adequate sensitivity and specificity.  
Other faecal markers of inflammation include calprotectin, S100A12, and lactoferrin. 
Although these three markers are not yet universally available, they provide a less-invasive 
method to assess gut inflammation. Normalisation of these markers can be used as markers 
of the success of therapy. Each of the measures can be used to assess the response to 
therapeutic intervention in children with UC. Calprotectin can also be helpful in assessing 
the risk of subsequent relapse of disease (Costa et al 2005).  
9. Principles of management of UC in children 
The overall aims of management of UC in children and adolescents are to control 
inflammation and to maintain remission, whilst ensuring that the child has normal growth 
and development. Ongoing inflammation will likely adversely impact upon growth in 
children and adolescents.  
As well as optimising growth, management should ensure normal pubertal development, 
and normal social and psychological health. Treatment side-effects must be avoided or 
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minimised: especially those side-effects that may in turn interfere with growth and 
development. Thus, therapeutic choices must be seen in the context not just of the child’s 
current disease status and disease location, but also in terms of growth, puberty, bone 
health, family setting, and psychological wellbeing. In addition to the critical importance of 
growth and nutrition in children, it is also crucial to ensure the avoidance of side effects in 
children who will face many years of disease and exposure to medications. One other 
element of the long term nature of these diseases, when commencing in childhood, is that 
reduction and control of the disease burden may help to avoid long-term disease related 
complications. One example of this is the increased risk of colonic cancer seen in the 
setting of long-standing colitis (colitis associated carcinoma), especially when 
uncontrolled.  
Due to the complex medical and social issues involved in the management and treatment of 
children and adolescents with CD or UC, care should be provided in a multi-disciplinary 
manner. In addition to the management of medical aspects by specialist paediatric 
gastroenterologists, universal attention must be paid to many other issues. These include 
growth and nutrition, normal development, attention to schooling and learning, 
psychosocial issues, coping and adjustment issues, and general well-being. In addition to 
the various direct effects of chronic UC upon the child or adolescent patient, these chronic 
illnesses may also impact adversely upon siblings and parents.  
These wide ranging and important issues mean that many key non-medical personnel also 
should be closely involved in the care of these children. These individuals include nursing 
staff (to provide key liaison and coordination roles), dietitians (growth and nutrition), social 
workers and psychologists (psychosocial and coping aspects).  Paediatric surgeons, 
pathologists and radiologists experienced and skilled in relevant aspects of paediatric UC 
also comprise key personnel contributing to the care of children with UC. The child’s 
general practitioner also plays an important role in the care of these children. Thus the 
management of all children with CD or UC should be facilitated within a context that 
provides access to each of these professionals. The system of care needs to be able to 
provide coordination of services, with good clear lines of communication between 
personnel.  
Further to the personnel requirements for an environment caring for children with CD and 
UC, appropriate support is also necessary. This includes adequate administration support 
(such as secretarial, outpatient booking staff and medical record staff), along with adequate 
record and database systems. This may include systems to ensure regular checking of 
required blood tests, or annual blood tests, or providing for clear records of complications or 
events. This might include the use of diagnostic checklists, pre-clinic review meetings, 
proformas for clinic review and systems to ensure regular monitoring requirements. These 
database and record keeping resources will provide for smooth seamless clinical 
management, and also for eventual transition to adult services and audit or research 
activities. 
A further key principle in the management of children with UC is that care needs to be 
firmly family focused. A child with UC needs to be seen in the context of their family. 
Parents and sometimes siblings will attend outpatient appointments with their child. 
Parents and the patient will be together involved in decision making or consideration of 
therapeutic choices. Furthermore, parents and the patient’s siblings will be directly and 
indirectly affected by the child’s condition. 
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10. Medical management of paediatric UC 
10.1 Induction and maintenance of remission in UC 
The therapies proven to have roles in the induction of remission of active UC in children are 
less numerous than those available for CD. Overall therapies can be considered as those 
used to induce remission and those used to maintain remission (Table 1).  
 
INDUCE REMISSION MAINTAIN REMISSION 
Corticosteroids Corticosteroids (especially topical) 
ASA ASA 
Tacrolimus (or cyclosporin) Azathioprine / 6-mercaptopurine 
Infliximab Methotrexate 
?Adalimumab ?Tacrolimus 
 ?Infliximab 
Table 1. Standard Therapies for UC in children and adolescents 
As in CD, the goal in the long term management of UC in children is to maintain remission 
and control of disease, along with ensuring optimisation of normal life events, whilst 
ensuring that medical therapy does not lead to adverse consequences. 
CS are most commonly used to induce remission, although ASA may have a role in mild 
disease. Tacrolimus, cyclosporin and infliximab may have roles in severe UC, as second line 
(rescue) therapy. Two therapies that have roles in paediatric CD (exclusive enteral nutrition 
and antibiotics) probably do not have roles in UC.   
5-ASA drugs often comprise the initial therapy used to maintain remission in childhood UC. 
When disease is not well-controlled with ASA drugs, then immunosuppressives would be 
indicated. Thiopurines (azathioprine or 6-mercaptopurine) are more often utilised, but 
methotrexate also has a role. Tacrolimus may also have benefits as a maintenance drug to 
keep control. 
10.2 Corticosteroids 
CS can be utilised in various routes for active UC. Oral CS in mild to moderate UC may lead 
to more rapid improvements than those seen in CD. CS (including topical delivery) may 
have roles in maintenance of remission. 
Standard CS therapy to induce remission involves oral prednisone or prednisolone with 
once daily dosing in the morning (doses as per Table 2). Budesonide, which has advantages 
over prednisone with less systemic absorption and side-effects, has been demonstrated to 
have a role in the management of ileal CD. The role of budesonide in the management of 
UC has been considered in several studies. Three of these studies were reviewed together 
in a recent Cochrane review: budesonide was shown to not be helpful for UC (Sherlock et 
al 2011).  Interestingly, however, budesonide as a MMX preparation was shown to be 
helpful in a study reported in abstract form at Digestive Diseases Week 2011 (Sandborn et 
al 2011).  
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IV Steroids 2 mg/kg/day (max 40 mg/day) once daily in morning (starting dose, 
then wean as appropriate) 
Budesonide 6-9 mg/day (then wean as appropriate) 
IV Steroids Hydrocortisone 2-4 mg/kg/day (q6h); Methylprednisolone 1-1.5 
mg/kg/day (q12h) 
Sulphasalazine 50-60 mg/kg/day (up to 3-4 grams daily) 
5-ASA 30-50 mg/kg/day 
Azathioprine Start 1 – 1.5 mg/kg/day, Increase to approx 2.5 mg/kg/day (max 200 
mg/day) 
6-MP Start 1 mg/kg/day, increase to around 1.5 mg/kg/day 
Methotrexate 15 mg / m2 (max 25 mg) weekly subcutaneous injection 
Tacrolimus Commence at 0.1 mg/kg/day in 2 divided doses orally 
 Usual dose 0.2 mg/kg/day in 2 divided doses (ongoing dose 
dependant on levels) 
Cyclosporin 3-8 mg/kg/dose Q12H 
Table 2. Standard doses for drugs used in Paediatric UC 
Severe UC often requires the administration of IV CS. Typically this would be given as 
methyprednisolone, with one or two doses daily, or six-hourly hydrocortisone. 
Methylprednisolone has the advantage of less mineralocorticoid effects. 
One study from Japan has evaluated pulse steroid therapy in children with UC (Kudo et al 
2011). This group retrospectively compared outcomes from children with UC treated with 
conventional methylprednisolone dosing to another group treated with megadose pulse 
therapy (20-30 mg/kg/day, to max of 1000 mg). Pulse therapy lead to more rapid response, 
with quicker reduction in PUCDAI scores, without any increase in side-effect profile. Pulse 
therapy, however, did not alter outcomes over the first 12 months after diagnosis compared 
to standard therapy. This retrospective data in a small group of patients would require 
replication and confirmation before broader use of this approach.  Other data looking at 
larger doses of corticosteroids have not suggested benefits.  
Topical CS is more often helpful in distal UC, where it has advantages of less systemic 
absorption and being directed straight to the area of inflammation. Steroid suppositories 
may be helpful in very distal disease, whereas enemas or foam preparations may have 
effects in left-sided disease. In these instances, topical CS may have benefits in treating 
active disease and in maintaining control. However, children may not tolerate the per-rectal 
administration route.  
10.3 Amino-salicylates   
This group of therapies includes sulphasalazine and the 5-aminosalicylate (5-ASA) drugs. 
Delivery routes include oral and rectal (suppository or enema). Packaging of the 5-ASA 
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drugs can provide distribution of the drug at different locations in the gastrointestinal tract. 
More recent variations of the 5-ASA drugs enable once daily dosing with equivalent efficacy 
to multiple dosing regimens. 
These drugs have roles in the induction and maintenance of remission in UC (Ford et al 
2011). Although there are many studies demonstrating efficacy of 5-ASA agents in adults 
with UC, there are few in children or adolescents. One study demonstrated 80% clinical 
remission with sulphasalazine at 1, 2 and 3 months and lower response to olsalazine at the 
same time points (Ferry et al. 1993). 
10.4 Thiopurines 
Azathioprine or 6-mercaptopurine are the most commonly used immunosuppressives in 
paediatric IBD. Although well-established as agents that modify disease course in children 
with moderate-severe CD when used early, there has been little data in paediatric UC.  
Seventy-five percent of a group of 32 children with UC in a British series received 
azathioprine (Howarth et al 2007).  Recently a prospective multi-centre study evaluated the 
outcomes of thiopurines in paediatric UC (Hyams et al 2011). This report included 394 
children with UC recruited at diagnosis from paediatric centres in USA. One hundred and 
ninety seven of this group received thiopurines (half within the first 3 months of diagnosis). 
Due to difficulties in follow-up or other reasons, just 133 of this cohort were re-evaluated 
after 12 months. Sixty-five of these 133 children were in remission at this time, without CS or 
rescue therapy. 
10.5 Methotrexate 
Methotrexate is also well established a second or third line agent for the maintenance of 
remission in CD. Only recently, however, has it also been considered for the maintenance of 
remission in UC. Two clinical trials are assessing the role of methotrexate in adult UC 
(Carbonnel 2011).  A recent retrospective report described the outcomes of methotrexate in a 
group of Canadian children with UC (Willot et al 2011). Four of the 16 children with UC or 
IBDU were in remission after six months of methotrexate therapy. A further report from 
Italy evaluated 32 children with UC who were treated with methotrexate (Aloi et al 2010). 
Response or remission was seen in 72% of the children by 3 months, with 50% at 12 months. 
Almost all of the children receiving steroids at the start of therapy were able to cease 
steroids by six months. Both these studies, however, were retrospective assessments of this 
drug in relatively small cohorts. Prospective studies are required to clarify the role of 
methotrexate in paediatric UC.   
Methotrexate is given as a once weekly subcutaneous injection. Six weeks is usually 
expected before onset of action, and sixteen weeks would be required before expecting the 
benefits of the drug. Folate supplementation (but not on the day of methotrexate 
administration) is required to prevent folate deficiency – this also may decrease upper gut 
side-effects. 
10.6 Infliximab and adalimumab 
The anti-Tumour necrosis factor-(TNF) alpha inhibitor Infliximab has been evaluated in 
adult and paediatric UC.  
A recent report demonstrated the benefits of infliximab in paediatric UC (Hyams et al 2010).  
The outcomes of 52 children recruited prospectively across several sites in USA were 
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followed for a median of 30 months. CS-free remission was seen in 38% of these children at 
12 months, with remission in 21% after 24 months. After 2 years of followup, 39% of this 
group had undergone colectomy. An Italian study has also reviewed their experience with 
infliximab in children with UC (Cucchiara et al 2008). These 22 children had been treated 
with infliximab using a three dose induction course and ongoing maintenance dosing (eight 
weekly). Some of the children had acute severe colitis with no response to CS, whilst others 
had a protracted course with/without CS dependency. Overall, 12 of the 22 children had 
full response with CS-free remission after 12 months and 6 others had partial response. 
Seven children required colectomy (only one during the acute period).   
A report in adults with UC unresponsive to CS demonstrated that adalimumab is also safe 
and effective in this context (Reinisch et al 2011). However, there is not yet data looking at 
adalimumab or other biologics in paediatric UC. 
10.7 Tacrolimus and cyclosporin (CSA) 
These calcineurin inhibitors are most typically used as rescue therapy in acute severe UC. 
Although CSA is favoured in adult protocols, tacrolimus has advantages of oral 
administration, quicker onset of action and a more tolerable side-effect profile. In the context 
of acute severe UC, tacrolimus can be used a bridge to allow the introduction of long-term 
immunosuppressive therapy (such as azathioprine). In addition, tacrolimus may have a role 
in the management of grumbling colitic symptoms and/or as a longer-term drug to 
maintain remission. 
Tacrolimus was evaluated in an open label multi-centre study as rescue therapy in children 
with UC (Bousvaros et al 2000). Two thirds of the 14 children responded, but less than half 
had long-term remission. More recently, a cohort of 46 children managed with tacrolimus 
was reviewed retrospectively (Watson et al 2011). Ninety-three percent of this group were 
discharged without requiring colectomy, and the probability of colectomy after tacrolimus 
therapy was 40% at 26 months. Side-effects in this cohort included hypertension, headaches, 
seizures, tremor and nephrotoxicity. Although not reported in this cohort, 
hypomagnesaemia is a further common side-effect. Tacrolimus therapy requires close 
monitoring of serum levels (aim to achieve 8-10 initially), with ongoing close monitoring of 
renal function, electrolytes, blood pressure, blood sugar and urinalysis. Magnesium 
supplementation may be required.  
10.8 Exclusive enteral nutrition 
This therapy involves the exclusive administration of a liquid diet for 6-8 weeks as sole 
therapy to induce remission. This therapy is well established as standard induction therapy 
for newly diagnosed CD in children. Although this therapy has benefits in colonic CD, there 
is less evidence for a role in UC. 
10.9 Novel therapies for UC 
Along with the roles of standard medical and surgical therapies has been increasing interest 
in novel therapies. Foremost of these is probiotic therapies. There is convincing animal and 
human evidence indicating that modifications to the intestinal flora can prevent or modulate 
gut inflammation. Recent studies have focused on VSL#3, a high-potency probiotic mixture, 
in adult and paediatric UC. A recent Italian study in adults with UC demonstrated that 
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VSL#3 supplementation was safe and effective, with reduction in disease activity scores and 
symptoms (Tursi et al 2010). An earlier paediatric study evaluated the same probiotic 
therapy in 29 children with newly-diagnosed active UC using a randomised placebo-
controlled design (Miele et al, 2009). Remission was observed in 93% of the children treated 
with VSL#3, compared to 36% of those who did not receive the probiotic. Less children 
receiving the probiotic relapsed over the followup period, and no adverse effects were 
attributed to the probiotic. It is not clear if these findings are specific to VSL#3, or able to be 
achieved with other probiotics, but are clearly encouraging as a safe and effective therapy 
for UC.   
11. Severe acute colitis 
Several recent publications have highlighted key aspects of acute severe colitis in children. 
Most important of these was a prospective multi-centre study conducted in North America 
(Turner et al 2010a). This study included 128 children admitted to one of 10 centres for 
severe UC – both as initial presentation and as subsequent relapse of disease. These children 
were assessed serially in terms of clinical and laboratory findings, disease activity scores 
and outcomes, both during hospitalisation and for up to 12 months subsequently.  All 
children were treated with intravenous corticosteroids as initial therapy. Thirty-seven 
children did not respond to corticosteroids: these children proceeded to receive secondary 
medical therapy (cyclosporin or infliximab) or underwent colectomy. Overall 9% of children 
had colectomy by discharge and 19% required this by 12 months follow-up. PUCAI scores 
calculated during hospitalisation in all children were predictive of response and outcomes. 
A score of greater than 45 on day 3 of admission predicted lack of response to 
corticosteroids. In contrast a score of greater than 70 on day 5 guided the start of rescue 
therapy.  
Serial stool samples in this cohort of children were analysed for a suite of faecal 
inflammatory markers (Turner et al 2010b). All four of the markers (calprotectin, S100A12, 
M2PK and lactoferrin) were greatly elevated in these children. M2PK provided the best 
predictive value for response to corticosteroids. However, none of these markers performed 
better than the PUCAI in this context. A further assessment of a subset of samples from this 
group of children evaluated faecal osteoprotegrin (OPG): when measured at day three faecal 
OPG was a good predictor of response to corticosteroids (Sylvester 2011). This marker has 
previously been evaluated in children with CD (Nahidi et al 2010).  
More recently a consensus statement from key European groups has been prepared (Turner 
et al 2011). This document outlines key recommendations and management pointers for 
acute severe colitis in children (Table 3).  
 
1. Stool evaluation should include standard culture and specific screening for C difficile 
2. CMV infection should be excluded endoscopically in children with steroid resistant 
disease 
3. Disease activity should be monitored regularly during admission, with frequent 
assessment of vital signs, completion of PUCAI scores daily and monitoring of key 
blood tests (ESR, full blood count, albumin and electrolytes) at admission and at 
subsequent intervals 
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4. Initial treatment should be with intravenous corticosteroids, with 
methylprednisolone (1-1.5 mg/kg/day, to max of 60 mgs as 1 or 2 daily doses) 
favoured due to less mineralocorticoid effect. 
5. Antibiotics are not indicated routinely but should be considered when sepsis 
suspected or  when toxic megacolon present 
6. There is no evidence for the routine use of prophylactic heparin to prevent 
thromboembolic events 
7. 5-ASA therapies should be interrupted at admission in known patients, or 
introduction delayed in newly diagnosed patients 
8. Regular diet should be continued, but nutritional support (enteral or parenteral) 
considered if inadequate oral intake. Oral intake should be ceased when surgery 
imminent and is contraindicated in toxic megacolon. 
9. Complications (such as perforation or toxic megacolon) should be considered in 
children with increasing or severe pain. Narcotics or non-steroidal anti-inflammatory 
drugs are not recommended in the setting of acute severe colitis. 
10. PUCAI scores can be used to monitor response and the need for secondary therapy. 
A score of >45 at day 3 indicates likely poor response to corticosteroids and a need to 
prepare for rescue therapy. A score of >65 on day 5 indicates a need to commence 
rescue therapy on that day. In children with PUCAI scores of between 35 and 60 at 
day 5, steroids can be continued for a further 2-5 days before secondary therapy 
should be considered. Children with scores of less than 35 points on day 5 are not 
likely to require rescue therapy 
11. Plain radiographs of the abdomen should be obtained in any child with clinical signs 
of toxicity and subsequently as indicated. The diagnostic criteria for toxic megacolon 
comprise radiological evidence colonic dilatation (>=56 mm) along with signs of 
toxicity. Urgent surgical review is required in all children with toxic megacolon. 
Conservative management is appropriate if the child has stable vital signs and there 
are no signs of sepsis. If signs of toxicity worsen, then immediate colectomy should 
be undertaken. Rescue medical therapies are not indicated in the setting of toxic 
megacolon. 
12. Rescue therapies include medical (infliximab or calcineurin inhibitors) and surgical 
(colectomy) options.  
13. Sequential medical rescue therapies are not recommended in children 
14. If colectomy is required in acute severe colitis in children, subtotal colectomy and 
ilesotomy is recommended. Pouch formation can subsequently be considered. 
15. Surgical complications can be reduced by avoiding delays in colectomy to enhance 
nutrition or to wean corticosteroids and the use of perioperative broad spectrum 
antibiotic coverage.  
 
Table 3. Recommendations from Consensus statement for the management of acute severe 
colitis in children (abridged from reference: Turner 2011) 
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12. Surgical management  
Colectomy may be required during childhood in children with UC. Indications include 
fulminant UC unresponsive to medical therapy, severe colitis complicated by toxic 
megacolon and/or perforation, chronic colitis unresponsive to medical agents and when 
pre-cancerous changes develop. One retrospective study has assessed clinical factors that 
might help in prognosticating the risk of colectomy (Moore et al 2011). In a cohort of 135 
children with UC, these authors showed that white blood count and haematocrit values at 
diagnosis were associated with colectomy at 3 years. A UC Risk Score was derived from 
these measurements. Risk assessment such as this required further prospective assessment 
in large numbers of children. 
Colectomy may be followed by ileal pouch formation as one or more steps. A two-step 
procedure might include colectomy and end-ileostomy initially followed by pouch 
formation. A new pouch may be protected by a defunctioning ileostomy, which is 
subsequently reversed (third step). Pelvic dissection in young individuals, as required for 
total colectomy, may be complicated by disruption to pelvic nerves and consequent effects 
upon fertility.  
A condition known as pouchitis may complicate an ileal pouch. Probiotics can be used to 
prevent or treat pouchitis. Antibiotics (e.g. metronidazole) are also useful for pouchitis. 
The outcomes of surgical management of UC in children have been considered in some 
recent reports. Newby et al reported that 17.6% of 72 children with UC underwent 1 or more 
major operations over the period of study, with a mean time of 1.92 years to the first 
procedure (Newby et al 2008). Fraser et al (Fraser et al 2010) retrospectively compared the 
outcomes of laparoscopic and open colectomy in a group of 44 children aged up 18 years of 
age. Twenty-seven of this group were diagnosed with UC – the remainder had various other 
surgical diagnoses. There were no differences between the technique in terms of 
postoperative abscess or sepsis, would infection of small bowel obstruction. The children 
having laparoscopic ileoanal reanastomosis and pouch formation had less pouchitis than 
those having open pouch formation (p=0.03). 
A second study (Lillehei et al 2010) evaluated QOL scores in children undergoing 
proctocolectomy and pouch formation. The children with UC and their parents reported low 
QOL scores pre-operatively that improved substantially with resection. This report did not 
evaluate other aspects of the outcomes of surgical intervention. 
13. Transition of adolescents with UC to adult services 
One of the last components of the management of adolescents with UC is preparing them 
for the move on from paediatric care to adult care. This transition is increasingly recognised 
as an important step in the overall management of young people with chronic diseases, such 
as UC (Viner 2008). The move from a family-focused multi-disciplinary model of care in the 
paediatric setting to the adult setting that typically features an individual-focused approach 
that may be office based and more rigid, with expectations of patient involvement. 
Preparation for this transition can include review of understanding of medications, 
knowledge of key aspects of disease management, and practical aspects of health care (such 
as renewal of scripts, learning how to organise appointments and health benefit applications 
if appropriate). A successful transition should lead to a more confident young person able to 
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better care for their own health and willing to take charge of their care. Further, it should 
also mean that less young people “fall between the cracks”, and ultimately lead to better 
quality of life and health outcomes.  
14. Conclusions 
Children and adolescents should be considered a distinct and special group of patients with 
numerous important clinical features, and with particular management needs and 
requirements. At this point in time, genetic evaluation is not part of routine clinical 
management. In time, however, analysis of mutations in key relevant genes will likely be 
considered routine. Such developments will serve to further differentiate paediatric UC 
from the condition in older individuals and perhaps will also assist in defining clinical 
subgroups that may indicate specialised therapeutic needs and/or provide key prognostic 
information.  
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